Last reviewed · How we verify

IWK Health Centre — Portfolio Competitive Intelligence Brief

IWK Health Centre pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bolus Phenylephrine/Ephedrine Treatment Bolus Phenylephrine/Ephedrine Treatment marketed Sympathomimetic amines / Vasopressors Alpha-1 adrenergic receptor (phenylephrine); Alpha and beta adrenergic receptors (ephedrine) Cardiovascular / Critical Care
Phenylephrine bolus Phenylephrine bolus marketed
Synera(TM) Synera(TM) marketed Topical local anesthetic Voltage-gated sodium channels Dermatology/Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American University of Beirut Medical Center · 1 shared drug class
  2. Brown, Theodore R., M.D., MPH · 1 shared drug class
  3. Eugene Y Rhee, MD · 1 shared drug class
  4. The University of Texas Health Science Center, Houston · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IWK Health Centre:

Cite this brief

Drug Landscape (2026). IWK Health Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/iwk-health-centre. Accessed 2026-05-17.

Related